NPS PHARMACEUTICALS INC (NPSP1)

Sector:
HEALTH CARE
Industry:
HEALTH CARE
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Francois Nader
Employees:
365
550 HILLS DRIVE, BEDMINSTER, NJ 07921
(908) 450-5300

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on pa...

Data derived from most recent annual or quarterly report
Market Cap 4.923 Billion Shares Outstanding107.1 Million Avg 30-day Volume 4.588 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.08
Price to Revenue16.9766 Debt to Equity0.7473 EBITDA15.984 Million
Price to Book Value28.4238 Operating Margin2.2538 Enterprise Value3.74 Billion
Current Ratio4.61 EPS Growth0.429 Quick Ratio3.83
1 Yr BETA 1.6802 52-week High/Low 0.0 / Profit Margin-3.8851
Operating Cash Flow Growth31.2798 Altman Z-Score11.3308 Free Cash Flow to Firm 8.001 Million
View SEC Filings from NPSP1 instead.

View recent insider trading info

Funds Holding NPSP1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NPSP1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

TOMBROS PETER G

  • Director
No longer subject to file 2015-02-21 0

GRONINGER JAMES G

  • Director
No longer subject to file 2015-02-21 0

BESHAR LUKE M EVP & CFO

  • Officer
No longer subject to file 2015-02-21 0

GRANADILLO PEDRO P

  • Director
No longer subject to file 2015-02-21 0

BONNEY MICHAEL W

  • Director
No longer subject to file 2015-02-21 0

GEMAYEL GEORGES

  • Director
No longer subject to file 2015-02-21 0

BROOM COLIN MD

  • Director
No longer subject to file 2015-02-21 0

ROGUS JOSEPH J SVP, GTO & SUPPLY CHAIN MNGMT

  • Officer
No longer subject to file 2015-02-21 0

SELISKER RACHEL R

  • Director
No longer subject to file 2015-02-21 0

PAUWELS ERIC PRESIDENT, NPS PHARMA INT'L

  • Officer
No longer subject to file 2015-02-21 0

NADER FRANCOIS PRESIDENT, CEO AND DIRECTOR

  • Officer
  • Director
No longer subject to file 2015-02-21 0

LEGAULT PIERRE

  • Director
No longer subject to file 2015-02-21 0

GARCEAU ROGER SVP & CMO

  • Officer
No longer subject to file 2015-02-21 0

CVIJIC CHRISTINE MIKAIL SVP, LEGAL AFFAIRS & GC

  • Officer
No longer subject to file 2015-02-21 0

GRAF SUSAN E VP,CORP DEVELOPMENT & STRATEGY

  • Officer
0 2015-02-21 0

FRIEDMAN ROBIN D SVP OF HUMAN RESOURCES

  • Officer
0 2015-02-21 0

FIRUTA PAUL E PRESIDENT, US COMM OPERATIONS

  • Officer
0 2015-02-21 0

MELROSE GLENN R SVP, HUMAN RESOURCES

  • Officer
26,971 2014-02-13 0

STRATEMEIER ED SVP & GENERAL COUNSEL

  • Officer
44,253 2014-02-13 0

COTTRELL SANDRA VP, REGULATORY AFFAIRS & DRUG

  • Officer
0 2012-12-21 0

KUHLA DONALD E

  • Director
15,225 2012-02-07 0

BRYAN NANCY SVP, COMMERCIAL OPERATIONS

  • Officer
0 2011-02-17 0

RACKEAR ANDREW D. SVP, GENERAL COUNSEL & SEC.

  • Officer
0 2009-01-20 0

DOBAK DOUGLAS N VP, REGULATORY AFFAIRS

  • Officer
0 2008-10-15 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
No longer subject to file 2008-09-19 0

STILLER CALVIN

  • Director
0 2008-04-15 0

COLES N ANTHONY PRESIDENT, COO & DIRECTOR

  • Officer
  • Director
220,066 2008-03-17 0

HARRIS ALAN G SVP, CHIEF MEDICAL OFFICER

  • Officer
0 2008-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments